GlassScriptPhysician profile
Aleksey A Androsov
NPI 1104258144
$4,821.19
in general payments reported to CMS, 2019-2025
23 companies · $732 in 2025
The $732 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,227 · 2020: $92.64 · 2021: $617 · 2022: $451 · 2023: $748 · 2024: $953 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,433.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $831.71 | 2022-2024 | |
| Sk Life Science, INC. | $454.80 | 2021-2024 | Xcopri |
| Emd Serono, INC. | $369.28 | 2019 | |
| Amgen INC. | $343.06 | 2019-2025 | Uplizna |
| Ucb, INC. | $297.79 | 2019-2025 | Nayzilam |
| Celgene Corporation | $233.09 | 2021-2024 | Zeposia |
| Novartis Pharmaceuticals Corporation | $216.59 | 2019-2020 | |
| Neurelis, INC. | $215.78 | 2021-2024 | Valtoco |
| Lilly USA, LLC | $205.61 | 2019-2024 | Kisunla |
| Biogen, INC. | $204.94 | 2023 | Vumerity, Tysabri |
| Genentech USA, INC. | $202.64 | 2019 | |
| Amneal Pharmaceuticals LLC | $124.86 | 2025 | Crexont |
| Janssen Biotech, INC. | $124.86 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $123.10 | 2025 | Zeposia |
| Sunovion Pharmaceuticals INC. | $123.00 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $121.61 | 2024 | |
| Eisai INC. | $120.60 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $118.66 | 2023 | Andexxa |
| Acadia Pharmaceuticals INC | $111.26 | 2024 | Nuplazid |
| Pfizer INC. | $109.14 | 2025 | |
| Janssen Pharmaceuticals, INC | $92.75 | 2021 | |
| Impel Pharmaceuticals INC. | $61.24 | 2022 | |
| Medtronic Vascular, INC. | $14.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aleksey Androsov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.